{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-001975","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.369860+00:00","generated_at":"2026-06-19T09:17:54.217050+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alkermes FY2022 revenue $1.11B, GAAP loss per share $0.97; guides FY2023 revenue $1.13-1.25B","bullets":["Q4 2022 total revenues $304.7M, GAAP net loss $0.17/share, non-GAAP diluted EPS $0.14.","FY2022 proprietary net sales: VIVITROL $379.5M (+10%), ARISTADA $302.1M (+10%), LYBALVI $96.0M (first full year).","FY2023 guidance: revenue $1.13-$1.25B, GAAP loss per share ($0.96)-($1.20), non-GAAP diluted EPS $0.00-$0.23.","New long-term profitability targets: FY2024 non-GAAP net income 25% of revenue, EBITDA margin 20%; FY2025 30% and 25%.","Plans to separate oncology business in H2 2023; arbitration with Janssen ongoing, interim award in company's favor."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-001975","json":"https://secwatch.observer/filing/0001564590-23-001975.json","markdown":"https://secwatch.observer/filing/0001564590-23-001975.md","text":"https://secwatch.observer/filing/0001564590-23-001975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/0001564590-23-001975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/alks-8k_20230216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T09:17:54.217050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"001f14e4e6496e50ee81849a1872a957ab974dbf","claim":"Alkermes plc. reported the quarter ended December 31, 2022 results: revenue $304.7 million, net income $28.3 million, EPS $0.17.","evidence_excerpt":"• Total revenues for the quarter were $304.7 million, compared to $324.5 million for the same period in the prior year. • Net sales of proprietary products for the quarter were $216.1 million, compared to $178.9 million for the same period in the prior year. o Net sales of VIVITROL were $102.0 million, compared to $92.0 million for the same period in the prior year, representing an increase of approximately 11%. o Net sales of ARISTADA 1 were $79.2 million, compared to $78.7 million for the same period in the prior year, representing an increase of approximately 1%. o Net sales of LYBALVI were $34.9 million, compared to $8.2 million for the same period in the prior year, following commercial launch in October 2021. • Total operating expenses for the quarter were $325.3 million, compared to $322.1 million for the same period in the prior year. • Net loss according to generally accepted accounting principles in the U.S. (GAAP) was $28.3 million for the quarter, or a basic and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/0001564590-23-001975-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$304.7 million"},{"label":"Net income","value":"$28.3 million"},{"label":"EPS","value":"$0.17"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"bf475322e81520f9b57385fea571f2382f919d8c","claim":"Alkermes plc. updated its the year ending December 31, 2023 guidance (initiated).","evidence_excerpt":"On February 16, 2023, Alkermes plc (the “Company”) announced financial results for the three months and year ended December 31, 2022 and financial expectations for the year ending December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/0001564590-23-001975-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ending December 31, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"dc3a426c192ed083c213da880ffb0ad347c5a3ac","claim":"Alkermes plc. reported the year ended December 31, 2022 results: revenue $1.11 billion, net income $158.3 million, EPS $0.97.","evidence_excerpt":"— Revenues of $1.11 Billion in 2022, GAAP Loss per Share of $0.97 and Diluted Non-GAAP Earnings per Share of $0.34 —","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/0001564590-23-001975-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$1.11 billion"},{"label":"Net income","value":"$158.3 million"},{"label":"EPS","value":"$0.97"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}